Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs.
Our clinical team is currently investigating Inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy, combination with pembrolizumab and combination with chemotherapy, as well as advancing EOS-448, our ADCC-enabled anti-TIGIT antibody antagonist in Phase 1 trials , in- patients with cancer.
Currently enrolling patients for Phase 2a studies in monotherapy
ClinicalTrials.gov Trial Identifier: NCT03873883
Multicenter, open-label, dose-escalation Phase 1/1b clinical study to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of Inupadenant in patients with advanced solid tumors.
Preparing Phase 1b/2a studies for 3Q20.
Multicenter, open-label, dose-escalation Phase 1b/2a clinical studies to evaluate the safety and tolerability, the MTD/RP2D, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of Inupadenant in combination with Keytruda® and chemotherapy in specific indications.
ClinicalTrials.gov Trial Identifier: NCT04335253
This Phase 1/2 study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers. Participants’ tumors will be sampled before treatment and during treatment, to identify and confirm biomarkers to be used in further clinical development. Following dose escalation and determination of the recommended Phase 2 dose, the study design allows for the seamless expansion of patient cohorts to evaluate the anti-tumor activity of EOS-448 in specific tumor types. The trial will be conducted at multiple clinical sites in Europe and is expected to enroll approximately 30 patients with advanced cancer in the dose escalation portion.
iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with KEYTRUDA®
- Study will evaluate the safety and efficacy of the combination of iTeos’ EOS100850 and Merck’s KEYTRUDA® (pembrolizumab) Gosselies, Belgium and Cambridge, Mass. – Dec. 12, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, announced
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
First cohort of patients with advanced cancer now dosed with EOS100850 - Target enrollment of 72 patients; initial clinical data expected in Q4 2019 Gosselies, Belgium and Cambridge, MA – April 17, 2019 – iTeos Therapeutics SA , a privately-held biotechnology company developing novel cancer